Ecnoglutide: The cAMP-Biased GLP-1 Driving 13% Weight Loss
Ecnoglutide is a once-weekly biased GLP-1 receptor agonist from Sciwind that delivered 13.2% weight loss in Phase 3. Here's how the SLIMMER and EECOH-1 data stack up.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on June 21, 2026
Our medical review process ensures clinical accuracy and patient safety.
Most of the obesity-drug pipeline is a contest over how many hormones one molecule can hit at once — GLP-1 plus GIP, GLP-1 plus glucagon, triple agonists stacking all three. Ecnoglutide takes a quieter, more surgical approach. It is a single-target GLP-1 receptor agonist, but it is engineered to activate that receptor in a biased way: it pushes hard on the intracellular signal that drives satiety and insulin secretion while deliberately under-recruiting the pathway that switches the receptor off. Developed by China's Sciwind Biosciences, ecnoglutide has now cleared two Phase 3 trials — one in obesity, one in type 2 diabetes — and its 13.2% weight-loss readout puts it firmly in the conversation with first-generation GLP-1 drugs, at what is expected to be a fraction of their price.
Evidence: "Ecnoglutide 2.4 mg reduced body weight by 13.2% from baseline at week 40 versus a 0.1% increase with placebo, with 87% of participants achieving at least 5% weight loss." — Ji L, et al. The Lancet Diabetes & Endocrinology. 2025. DOI: 10.1016/S2213-8587(25)00141-X
What "Biased" Actually Means for Ecnoglutide
Every GLP-1 receptor agonist — semaglutide included — triggers two competing downstream events when it binds the receptor. The first is cyclic AMP (cAMP) signaling, the cascade that ramps up insulin release and dials down appetite. The second is β-arrestin recruitment, which tags the activated receptor for internalization, pulling it inside the cell and blunting further signaling. Conventional agonists fire both pathways more or less proportionally, so the receptor partly desensitizes itself even as it works.
Ecnoglutide is designed to break that symmetry. It is a long-acting GLP-1 analog tuned to favor cAMP production while minimizing β-arrestin recruitment — a property pharmacologists call "signaling bias." The practical consequence is that the receptor stays on the cell surface longer and keeps signaling, which in preclinical and clinical work translates into stronger glucose-lowering and weight effects per unit of drug.
Evidence: "Ecnoglutide is a cAMP signalling-biased GLP-1 analogue hypothesized to enhance efficacy through reduced internalisation of the GLP-1 receptor and enhanced insulin secretion." — Zhu D, et al. Nature Communications. 2026. DOI: 10.1038/s41467-025-68165-7
This is a genuinely different design philosophy from the oral and injectable GLP-1 agonists already on the market, which were optimized for half-life and binding affinity rather than for the quality of the signal once bound. Whether biased agonism delivers a durable clinical advantage over brute-force dosing is the open question — but the early efficacy numbers are why ecnoglutide is being watched closely.
SLIMMER: The Phase 3 Obesity Data
The pivotal weight-loss evidence comes from SLIMMER, a multicentre, randomized, double-blind, placebo-controlled Phase 3 trial. It enrolled 664 adults (aged 18–75) with overweight or obesity and without diabetes, randomizing them to once-weekly subcutaneous ecnoglutide at 1.2 mg, 1.8 mg, or 2.4 mg, or placebo, for 40 weeks. The results, presented at the American Diabetes Association's 85th Scientific Sessions and published simultaneously in The Lancet Diabetes & Endocrinology, showed a clean dose-response.
The numbers that matter
| Endpoint (SLIMMER, Week 40) | 1.2 mg | 1.8 mg | 2.4 mg | Placebo |
|---|---|---|---|---|
| Mean body-weight change | −9.1% | −10.9% | −13.2% | +0.1% |
| Achieved ≥5% weight loss | 77% | 84% | 87% | 16% |
| Dosing frequency | Weekly | Weekly | Weekly | Weekly |
A 13.2% reduction at the top dose over 40 weeks is a serious result for a single-pathway GLP-1 agonist, and weight loss had not visibly flattened by the end of the trial — a hint that longer dosing windows could push the figure higher. The dose-response was orderly: each step up in dose bought additional weight loss and a higher proportion of responders, which is what regulators want to see before approval.
Tolerability tracked the rest of the class. Treatment-emergent adverse events occurred in roughly 93% of ecnoglutide recipients versus 84% on placebo, driven by mild-to-moderate gastrointestinal effects — nausea, diarrhea, and vomiting concentrated during dose escalation. Only ten participants discontinued for adverse events across the whole trial, so the side-effect burden, while real, rarely forced patients to quit. These are the same GLP-1 side effects seen with semaglutide and tirzepatide, neither better nor dramatically worse on the available data.
EECOH-1 and the Diabetes Story
Ecnoglutide's second Phase 3 trial, EECOH-1, tested the drug as monotherapy in people with type 2 diabetes. It randomized 211 participants across 32 Chinese centers to ecnoglutide 0.6 mg, 1.2 mg, or placebo, with a 24-week double-blind core followed by a 28-week open-label extension out to 52 weeks. The glycemic results were strong and, again, dose-dependent.
| Endpoint (EECOH-1, Week 24) | 0.6 mg | 1.2 mg | Placebo |
|---|---|---|---|
| HbA1c change from baseline | −1.96% | −2.43% | −0.87%* |
| Reached HbA1c <7% | 68.1% | 80.3% | 21.1% |
| Body-weight change | −3.04 kg | −3.21 kg | −1.45 kg |
*Treatment differences versus placebo were −1.09% (0.6 mg) and −1.56% (1.2 mg).
An HbA1c drop of nearly 2.5 percentage points with the 1.2 mg dose, and four out of five patients reaching the standard <7% target, place ecnoglutide among the more potent GLP-1 monotherapies for glycemic control. Importantly, the trial reported no severe hypoglycemia and no pancreatitis — the safety signals that matter most for a diabetes drug. These findings built directly on the earlier Phase 2 program, which had already shown HbA1c reductions up to 2.39% over 20 weeks and established the once-weekly dosing rationale.
Evidence: "Once-weekly ecnoglutide produced statistically significant HbA1c reductions from baseline of −1.81%, −1.90%, and −2.39% at the 0.4, 0.8, and 1.2 mg doses versus −0.55% for placebo (P < 0.0001) over 20 weeks." — Zhu D, et al. Nature Communications. 2024. DOI: 10.1038/s41467-024-52353-y
A 2026 systematic review and meta-analysis pooling the diabetes data reinforced the consistency of the glycemic and weight effects across trials, supporting the case that the results are reproducible rather than a single fortunate readout.
How Ecnoglutide Stacks Up Against the Leaders
The honest comparison requires matching trial lengths, and here ecnoglutide's numbers come from a shorter 40-week study than the landmark 68- and 72-week obesity trials that defined the field. Read with that caveat, ecnoglutide sits a notch below tirzepatide and roughly level with — to slightly below — semaglutide, while its weight curve was still descending at the point its trial ended.
| Drug | Highest reported weight loss | Trial duration | Target(s) |
|---|---|---|---|
| Ecnoglutide (2.4 mg) | 13.2% | 40 weeks | GLP-1 (biased) |
| Semaglutide (2.4 mg) | 14.9% | 68 weeks | GLP-1 |
| Tirzepatide (15 mg) | 20.9% | 72 weeks | GLP-1 + GIP |
Evidence: "Once-weekly semaglutide 2.4 mg produced a mean 14.9% reduction in body weight versus 2.4% with placebo at week 68 in adults without diabetes." — Wilding JPH, et al. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183
Evidence: "Tirzepatide produced mean weight reductions of up to 20.9% at the 15 mg dose over 72 weeks in adults with obesity and without diabetes." — Jastreboff AM, et al. New England Journal of Medicine. 2022. DOI: 10.1056/NEJMoa2206038
Where ecnoglutide could compete is not peak efficacy but access. It is being developed by a domestic Chinese manufacturer for the world's largest type 2 diabetes population, and peptide GLP-1s made at scale in China are positioned to undercut Western branded pricing substantially. Sciwind is also advancing an oral tablet formulation of ecnoglutide through early trials, which — if successful — would put it in the same convenience tier as the emerging oral GLP-1 pills. For a drug class whose real-world impact is throttled by cost and supply, a cheaper, equally effective option matters as much as another point of weight loss. The same logic is driving the broader wave of Chinese metabolic-drug development now entering late-stage trials.
Key Takeaways
- Ecnoglutide is a once-weekly, cAMP signaling-biased GLP-1 receptor agonist — it favors the satiety-and-insulin pathway while minimizing the β-arrestin signal that desensitizes the receptor.
- Phase 3 SLIMMER delivered 13.2% weight loss at 40 weeks at the 2.4 mg dose, with 87% of participants losing at least 5% of body weight and the curve still trending down.
- Phase 3 EECOH-1 cut HbA1c by up to 2.43% in type 2 diabetes, with 80% of patients reaching the <7% target and no severe hypoglycemia or pancreatitis.
- Tolerability mirrors the class — mostly mild-to-moderate gastrointestinal effects during dose escalation, with few discontinuations.
- The strategic edge is cost and access, not peak efficacy: a China-manufactured GLP-1 with an oral version in development could expand affordable access where price currently limits treatment.
Ecnoglutide will not dethrone tirzepatide on raw weight loss, and its longest trial is shorter than the studies that built the GLP-1 category. But it makes a real case that how a GLP-1 receptor is activated — not just how hard — can shape clinical results, and it brings a credible, lower-cost option toward markets where the current generation remains out of reach for most patients. As regulatory submissions in China advance, it is one of the clearest signs that the second wave of GLP-1 therapy will be defined as much by access as by efficacy.
References
- Ji L, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology. 2025;13(9):777-789. DOI: 10.1016/S2213-8587(25)00141-X
- Zhu D, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nature Communications. 2026;17:1420. DOI: 10.1038/s41467-025-68165-7
- Zhu D, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Communications. 2024;15:8408. DOI: 10.1038/s41467-024-52353-y
- Kumar A, et al. Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Endocrinology, Diabetes & Metabolism. 2026. DOI: 10.1002/edm2.70217
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
Last updated: 2026-06-21 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.